The challenge of improving the efficacy of measles vaccine

Acta Tropica

Volumn 85, Issue 1, 2003, Pages 1-17

  Garly, May Lill ^a,b   Aaby, Peter ^a,b  

^a Projecto de Saúde Bandim ^*  (Guinea-Bissau)

^b DEPARTMENT OF EPIDEMIOLOGY RESEARCH   (Denmark)

Author keywords

Developing countries; Eradication; Measles vaccine; Non specific beneficial effects; Revaccination; Vaccine efficacy

Indexed keywords

MEASLES VACCINE;

DISEASE CONTROL; MEASLES; PERFORMANCE ASSESSMENT; VACCINATION;

ANTIBODY BLOOD LEVEL; DEVELOPING COUNTRY; DISEASE PREDISPOSITION; DRUG EFFICACY; ERADICATION THERAPY; HOSPITAL INFECTION; HUMAN; IMMUNITY; MEASLES; REVIEW; VACCINATION; WESTERN HEMISPHERE;

AGE FACTORS; HUMANS; INFANT; MEASLES; MEASLES VACCINE; TREATMENT OUTCOME; VACCINATION; VITAMIN A; WORLD HEALTH ORGANIZATION;

EID: 0037214014     PISSN: 0001706X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0001-706X(02)00261-9     Document Type: Review

References (149)

1. Aaby P., Bukh J., Lisse I.M., Smits A.J. Measles mortality, state of nutrition, and family structure: a community study from Guinea-Bissau. J. Infect. Dis. 147:1983;693-701.
2. Aaby P., Bukh J., Lisse I.M., Smits A.J. Measles vaccination and reduction in child mortality: a community study from Guinea-Bissau. J. Infect. 8:1984;13-21.
3. Aaby P., Bukh J., Lisse I.M., Smits A.J. Overcrowding and intensive exposure as determinants of measles mortality. Am. J. Epidemiol. 120:1984;49-63.
4. Aaby P., Bukh J., Lisse I.M., Smits A.J., Gomes J., Fernandes M.A., Indi F., Soares M. Determinants of measles mortality in a rural area of Guinea-Bissau: crowding, age, and malnutrition. J. Trop. Pediatr. 30:1984;164-168.
5. Aaby P., Bukh J., Hoff G., Leerhoy J., Lisse I.M., Mordhorst C.H., Pedersen I.R. High measles mortality in infancy related to intensity of exposure. J. Pediatr. 109:1986;40-44.
6. Aaby P., Bukh J., Leerhoy J., Lisse I.M., Mordhorst C.H., Pedersen I.R. Vaccinated children get milder measles infection: a community study from Guinea-Bissau. J. Infect. Dis. 154:1986;858-863.
7. Aaby P., Bukh J., Lisse I.M., Seim E., de Silva M.C. Increased perinatal mortality among children of mothers exposed to measles during pregnancy. Lancet. 1:1988;516-519.
8. Aaby P., Jensen T.G., Hansen H.L., Kristiansen H., Tharup J., Poulsen A., Sodemann M., Jakobsen M., Knudsen K., Clotilde da Silva M., et al. Trial of high-dose Edmonston-Zagreb measles vaccine in Guinea-Bissau: protective efficacy. Lancet. 2:1988;809-811.
9. Aaby P., Pedersen I.R., Knudsen K., da Silva M.C., Mordhorst C.H., Helm Petersen N.C., Hansen B.S., Tharup J., Poulsen A., Sodemann M., et al. Child mortality related to seroconversion or lack of seroconversion after measles vaccination. Pediatr. Infect. Dis. J. 8:1989;197-200.
10. Aaby P., Knudsen K., Jensen T.G., Tharup J., Poulsen A., Sodemann M., da Silva M.C., Whittle H.C. Measles incidence, vaccine efficacy, and mortality in two urban African areas with high vaccination coverage. J. Infect. Dis. 162:1990;1043-1048.
11. Aaby P., Andersen M., Sodemann M., Jakobsen M., Gomes J., Fernandes M. Reduced childhood mortality after standard measles vaccination at 4-8 months compared with 9-11 months of age. Br. Med. J. 307:1993;1308-1311.
12. Aaby P., Knudsen K., Whittle H.C., Lisse I.M., Thaarup J., Poulsen A., Sodemann M., Jakobsen M., Brink L., Gansted U., Permin A., Jensen T.G., Andersen H., da Silva M.C. Long-term survival after Edmonston-Zagreb measles vaccination in Guinea-Bissau: increased female mortality rate. Pediatrics. 122:(8):1993;904-908.
13. Aaby P., Samb B., Simondon F., Knudsen K., Seck A.M., Bennett J., Whittle H.C. Divergent mortality for male and female recipients of low-titer and high-titer measles vaccines in rural Senegal. Am. J. Epidemiol. 138:1993;746-755.
14. Aaby P., Samb B., Simondon F., Seck A.M.C., Knudsen K., Whittle H.C. Non-specific beneficial effect of measles immunisation: analysis of mortality studies from developing countries. Br. Med. J. 311:1995;481-485.
15. Aaby P., Samb B., Andersen M., Simondon F. No long-term excess mortality after measles infection: a community study from Senegal. Am. J. Epidemiol. 143:(10):1996;1035-1041.
16. Aaby P., Samb B., Simondon F., Knudsen K., Seck A.M., Bennett J., Markowitz L., Whittle H. A comparison of vaccine efficacy and mortality during routine use of high-titre Edmonston-Zagreb and Schwarz standard measles vaccines in rural Senegal. Trans. R. Soc. Trop. Med. Hyg. 90:(3):1996;326-330.
17. Aaby P., Cisse B., Simondon F., Samb B., Soumare M., Whittle H.C. Waning of vaccine-induced immunity: is it a problem in Africa? Am. J. Epidemiol. 149:(4):1999;304-305.
18. Ahmad K. Measles epidemic sweeps through Afghanistan. Lancet. 355:2000;1439.
19. Al-Mazrou Y.Y., Al-Jeffri M., Ahmed O.M.M., Aziz K.M.S., Mishkas A.H. Measles Immunization: Early Two-doses Policy Experience. J. Trop. Pediatr. 45:(2):1999;98-104.
20. Anderson P. Another media scare about MMR vaccine hits Britain. Br. Med. J. 318:(7198):1999;1578.
21. Arya S.C. Human contact with cattle, dogs and monkeys and genetic diversity of measles viruses. Comp. Immunol. Microbiol. Infect. Dis. 23:(2):2000;125-127.
22. Atabani S.F., Byrnes A.A., Jaye A., Kidd I.M., Magnusen A.F., Whittle H., Karp C.L. Natural measles causes prolonged suppression of interleukin-12 production. J. Infect. Dis. 184:(1):2001;1-9.
23. Atmar R.L., Englund J.A., Hammill H. Complications of measles during pregnancy. Clin. Infect. Dis. 14:1992;217-226.
24. Bahl R., Kumar R., Bhandari N., Kant S., Srivastava R., Bhan M.K. Vitamin A administered with measles vaccine to nine-month-old infants does not reduce vaccine immunogenicity. J. Nutr. 129:(8):1999;1569-1573.
25. Benn C.S., Aaby P., Balé C., Olsen J., Michaelsen K.F., George E., Whittle H.C. Randomised trial of effect of vitamin A supplementation on antibody response to measles vaccine in Guinea-Bissau, West Africa. Lancet. 350:(9071):1997;101-105.
26. Benn C.S., Balde A., George E., Kidd M., Whittle H., Lisse I.M., Aaby P. Effect of vitamin A supplementation on measles-specific antibody levels in Guinea-Bissau. Lancet. 359:(9314):2002;1313-1314.
27. Bennett J., Whittle H.C., Samb B., Cisse B., Simondon F., Aaby P. Seroconversions in unvaccinated infants: further evidence for subclinical measles from vaccine trials in Niakhar, Senegal. Int. J. Epidemiol. 28:(1):1999;147-151.
28. Bennett J.V., Cutts F.T., Katz S.L. Edmonston-Zagreb measles vaccine: a good vaccine with an image problem. Pediatrics. 104:(5 Pt 1):1999;1123-1124.
29. Bennett J.V., de Castro J.F., Valdespino-Gomez J.L., Garcia-Garcia M.L., Islas-Romero R., Echaniz-Aviles G., Jimenez-Corona A., Sepulveda-Amor J. Aerosolized measles and measles-rubella vaccines induce better measles antibody booster responses than injected vaccines: randomized trials in Mexican schoolchildren. Bull. Who. 80:(10):2002;806-812.
30. Berkelhamer S., Borock E., Elsen C., Englund J., Johnson D. Effect of highly active antiretroviral therapy on the serological response to additional measles vaccinations in human immunodeficiency virus-infected children. Clin. Infect. Dis. 32:(7):2001;1090-1094.
31. Berry S., Hernandez H., Kanashiro R., Campos M., Azabache V., Gomez G., Gutierrez M., Weirs B., de Quadros C., Halsey N.A. Comparison of high titer Edmonston-Zagreb, Biken-CAM and Schwarz measles vaccines in Peruvian infants. Pediatr. Infect. Dis. J. 11:1992;822-827.
32. Bhaskaram P., Rao K.V. Enhancement in seroconversion to measles vaccine with simultaneous administration of vitamin A in 9-months-old Indian infants. Indian J. Pediatr. 64:(4):1997;503-509. In Process Citation.
33. Biellik R.L., Clements C.J. Strategies for minimizing nosocomial measles transmission. Bull. Who. 75:(4):1997;367-375.
34. Black F.L., Berman L.L., Borgono J.M., Capper R.A., Carvalho A.A., Collins C., Glover O., Hijazi Z., Jacobson D.L., Lee Y.L. Geographic variation in infant loss of maternal measles antibody and in prevalence of rubella antibody. Am. J. Epidemiol. 124:(3):1986;442-452.
35. Bolotovski V.M., Grabowsky M., Clements C.J., Albrecht P., Brenner E.R., Zargaryantzs A.I., Litvinov S.K., Mikheyeva I.V. Immunization of 6 and 9 month old infants with AIK-C, Edmonston-Zagreb, Leningrad-16 and Schwarz strains of measles vaccine. Int. J. Epidemiol. 23:(5):1994;1069-1077.
36. Böttiger M., Christenson B., Romanus V., Taranger J., Strandell A. Swedish experience of two-dose vaccination programme aiming at eliminating measles, mumps and rubella. Br. Med. J. 295:1987;1264-1267.
37. Caceres V.M., Strebel P.M., Sutter R.W. Factors determining prevalence of maternal antibody to measles virus throughout infancy: a review. Clin. Infect. Dis. 31:(1):2000;110-119.
38. Cénac A., Develoux M., Djibo A. Chloroquine treatment of malaria does not increase antibody response to measles vaccination. A controlled study of 580 rural children living in an endemic malaria area. Trans. R. Soc. Trop. Med. Hyg. 82:1988;405.
39. Chen R.T., Markowitz L.E., Albrecht P., Stewart J.A., Mofenson L.M., Preblud S.R., Orenstein W.A. Measles antibody: reevaluation of protective titers. J. Infect. Dis. 162:(5):1990;1036-1042.
40. Chen R.T., Weierbach R., Bisoffi Z., Cutts F.T., Rhodes P., Ramaroson S., Ntembagara C., Bizimana F. A Post-honeymoon-period measles outbreak in Muyinga sector, Burundi. Int. J. Epidemiol. 23:(1):1994;185-193.
41. Cisse B., Aaby P., Simondon F., Samb B., Soumaré M., Whittle H.C. Role of schools in the transmission of measles in rural Senegal: implications for measles control in developing countries. Am. J. Epidemiol. 149:(4):1999;295-301.
42. Clemens J.D., Stanton B.F., Chakraborty J., Chowdhury S., Rao M.R., Ali M., Zimicki S., Wojtyniak B. Measles vaccination and childhood mortality in rural Bangladesh. Am. J. Epidemiol. 128:(6):1988;1330-1339.
43. Clements C.J., Cutts F.T. The epidemiology of measles: 30 years of vaccination. Curr. Top. Microbiol. Immunol. 191:1995;13-33.
44. Coovadia H.M., Kiepiela P., Wesley A.G. Immunity to and infant mortality from measles. South African Med. J. 65:1984;918-921.
45. Cutts F.T., Grabowsky M., Markowitz L.E. The effect of dose and strain of live attenuated measles vaccines on serological responses in young infants. Biologicals. 23:1995;95-106.
46. Cutts F.T., Clements C.J., Bennett J.V. Alternative routes of measles immunization: a review. Biologicals. 25:(3):1997;323-338.
47. Cutts F.T., Henao-Restrepo A., Olive J.M. Measles elimination: progress and challenges. Vaccine. 17:(Suppl 3):1999;S47-S52.
48. Davey S. Measles eradication still a long way off. Bull. Who. 79:(6):2001;584-585.
49. de Quadros C.A., Hersh B.S., Nogueira A.C., Carrasco P.A., da Silveira C.M. Measles eradication: experience in the Americas. Bull. Who. 76:(Suppl 2):1998;47-52.
50. Desgrées du Loû A., Pison G., Aaby P. Role of immunizations in the recent decline in childhood mortality and the changes in the female/male mortality ratio in rural Senegal. Am. J. Epidemiol. 142:(6):1995;643-652.
51. Diallo S., Denis F., Ndir O., Victorius A. Paludisme congénital et séroconversion après vaccination antirougeoleuse. Dakar Médical. 28:(1):1983;143-147.
52. Dilraj A., Cutts F.T., de Castro J.F., Wheeler J.G., Brown D., Roth C., Coovadia H.M., Bennett J.V. Response to different measles vaccine strains given by aerosol and subcutaneous routes to schoolchildren: a randomised trial. Lancet. 355:(9206):2000;798-803.
53. Expanded Programme on Immunization 1982. The optimal age for measles immunization, Wkly-Epidemiol-Rec., vol. 57, pp. 89-91.
54. Expanded Programme on Immunization 1992. Safety of high-titre measles vaccines, Wkly-Epidemiol-Rec., vol. 67, (48), pp. 357-361.
55. Expanded Programme on Immunization 1993. Post-exposure prophylaxis, vol. EPI/TECHCOM/WP/93.19.
56. Expanded Programme on Immunization and Global advisory group 1990. Measles control, Wkly-Epidemiol-Rec., vol. 65, pp. 5-12.
57. Fine P.E.M. Bacille Calmette-Guerin vaccines: a rough guide. Clin. Infect. Dis. 20:(1):1995;11-14.
58. Garenne M., Cantrelle P. Rougeole et mortalité au Senegal: étude de l′impact de la vaccination effectué a Khombole 1965-1968 sur la survie des enfants. Cantrelle P., et al. Estimation de la mortalité du jeune enfant (0-5 ans) pour guider les actions de santé dans les pays en developpmement. 1986;515-532 INSERM, Paris.
59. Garly, M.-L. 1999. Specific and Non-specific Effects of the Standard-titre Measles Vaccine and the BCG Vaccine. Implications for the Expanded Programme on Immunization. PhD-Thesis, University of Copenhagen.
60. Garly M.-L., Martins C.L., Balé C., da Costa F., Dias F., Whittle H.C., Aaby P. Early two-dose measles vaccination schedule in Guinea-Bissau: good protection and coverage in infancy. Int. J. Epidemiol. 28:(2):1999;347-352.
61. Garly M.-L., Bale C., Martins C.L., Monteiro M., George E., Kidd M., Dias F., Aaby P., Whittle H.C. Measles antibody responses after early two dose trials in Guinea-Bissau with Edmonston-Zagreb and Schwarz standard-titre measles vaccine: better antibody increase from booster dose of the Edmonston-Zagreb vaccine. Vaccine. 19:(15-16):2001;1951-1959.
62. Greenwood A.M., Greenwood B.M., Bradley A.K., Ball P.A.J., Gilles H.M. Enhancement of the immune response to meningococcal polysaccharide vaccine in a malaria endemic area by administration of chloroquine. Ann. Trop. Med. Parasitol. 75:(2):1981;261-263.
63. Guris D., McCready J., Watson J.C., Atkinson W.L., Heath J.L., Bellini W.J., Polloi A. Measles vaccine effectiveness and duration of vaccine-induced immunity in the absence of boosting from exposure to measles virus. Pediatr. Infect. Dis. J. 15:(12):1996;1082-1086.
64. Halsey N.A., Boulos R., Mode F., Andre J., Bowman L., Yaeger R.G., Toureau S., Rohde J., Boulos C. Response to measles vaccine in Haitian infants 6-12 months old. New Engl. J. Med. 313:(9):1985;544-549.
65. Harris M.F. The safety of measles vaccine in severe illness. South African Med. J. 55:1979;38.
66. Hartter H.K., Oyedele O.I., Dietz K., Kreis S., Hoffman J.P., Muller C.P. Placental transfer and decay of maternally acquired antimeasles antibodies in Nigerian children. Pediatr. Infect. Dis. J. 19:(7):2000;635-641.
67. Hersh B.S., Tambini G., Nogueira A.C., Carrasco P., de Quadros C.A. Review of regional measles surveillance data in the Americas, 1996-99. Lancet. 355:(9219):2000;1943-1948.
68. Holt E.A., Boulos R., Halsey N.A., Boulos L.-M., Boulos C. Childhood survival in Haiti: protective effect of measles vaccination. Pediatrics. 85:(2):1990;188-194.
69. Holt E.A., Moulton L.H., Siberry G.K., Halsey N.A. Differential mortality by measles vaccine titer and sex. J. Infect. Dis. 168:1993;1087-1096.
70. Hull H.F., Williams P.J., Oldfield F. Measles mortality and vaccine efficacy in rural West Africa. Lancet. i:1983;972-975.
71. Hussey G.D., Klein M. A randomized, controlled trial of vitamin A in children with severe measles. New Engl. J. Med. 323:(3):1990;160-164.
72. Ishiwada N., Addae M.M., Tetteh J.K., Yempewu S.M., Ofori-Adjei D., Kamiya H., Akanmori B.D. Vaccine-modified measles in previously immunized children in Accra, Ghana: clinical, virological and serological parameters. Trop. Med. Int. Health. 6:(9):2001;694-698.
73. Jensen T.G., Whittle H.C., Mordhorst C.H., Pedersen I.R., Thaarup J., Poulsen A., Sodemann M., Jakobsen M., Brink L., Gansted U., Permin A., Clotilde da Silva M., Aaby P. Trials of Edmonston-Zagreb measles vaccine in Guinea-Bissau: serological responses following vaccination with Edmonston-Zagreb strain at 4-8 months versus vaccination with Schwarz strain at 9-12 months of age. Vaccine. 12:(11):1994;1026-1031.
74. Kabir Z., Long J. Child mortality rates in rural India: an experience from the Ballabgarh project. J. Trop. Pediatr. 48:2002;178-180.
75. Kacica M.A., Venezia R.A., Miller J., Hughes P.A., Lepow M.L. Measles antibodies in women and infants in the vaccine era. J. Med. Virol. 45:(2):1995;227-229.
76. Kamat M., Pyati S., Pildes R.S., Jacobs N., Luayon M., Muldoon R., Levy P.S. Measles antibody titers in early infancy. Arch. Pediatr. Adolesc. Med. 148:(7):1994;694-698.
77. Kaninda A.V., Legros D., Jataou I.M., Malfait P., Maisonneuve M., Paquet C., Moren A. Measles vaccine effectiveness in standard and early immunization strategies, Niger, 1995. Pediatr. Infect. Dis. J. 17:(11):1998;1034-1039.
78. Koenig M.A., Khan M.A., Wojtyniak B., Clemens J.D., Chakraborty J., Fauveau V., Phillips J.F., Akbar J., Barua U.S. Impact of measles vaccination on childhood mortality in rural Bangladesh. Bull. Who. 68:(4):1990;441-447.
79. Kristensen I., Aaby P., Jensen H. Routine vaccinations and child survival: follow up study in Guinea- Bissau, West Africa. Br. Med. J. 321:(7274):2000;1435-1438.
80. Lane H.C., Montagne J.L., Fauci A.S. Bioterrorism: a clear and present danger. Nat. Med. 7:(12):2001;1271-1273.
81. Lennon J.L., Black F.L. Maternally derived measles immunity in era of vaccine-protected mothers. J. Pediatr. 108:(5 Pt 1):1986;671-676.
82. Leon M.E., Ward B., Kanashiro R., Hernandez H., Berry S., Vaisberg A., Escamilla J., Campos M., Bellomo S., Azabache V. Immunologic parameters 2 years after high-titer measles immunization in Peruvian children. J. Infect. Dis. 168:(5):1993;1097-1104.
83. Maldonado Y.A., Lawrence E.C., DeHovitz R., Hartzell H., Albrecht P. Early loss of passive measles antibody in infants of mothers with vaccine-induced immunity. Pediatrics. 96:(3 Pt 1):1995;447-450.
84. Markowitz L.E., Sepulveda. Immunization of 6-month-old infants with different doses of Edmonston-Zagreb and Schwarz vaccines. New Engl. J. Med. 322:1990;580-587.
85. Markowitz L.E., Albrecht P., Rhodes P., Demonteverde R., Swint E., Maes E.F., Powell C., Patriarca P.A. Changing levels of measles antibody titers in women and children in the United States: impact on response to vaccination. Kaiser Permanente Measles Vaccine Trial Team. Pediatrics. 97:(1):1996;53-58.
86. Martins, C.L. 2002. Níveis de Anticorpos Contra o Sarampo Entre as Mulheres em Idade Fértil na Populacão da Guiné-Bissau Expostas a Sarampo Natural e a Imunizacão Contra Sarampo, Master of Epidemiology, Universidad de Rio de Janeiro, Brazil.
87. Migasena S., Simasathien S., Samakoses R., Pitisuttitham P., Heath J., Bellini W.J., Bennett J. Adverse impact of infections on antibody responses to measles vaccination. Vaccine. 16:(6):1998;647-652.
88. Monjour L., Bourdillon F., Froment A., Daniel-Ribeiro C., Tirard S., Datry A., Chastang C., Tselentis Y., Gentilini M. Measles vaccination in the Sudan-Sahel region of Africa. Absence of the immunodepressive effect of malaria. Pathol. Biol. (Paris). 33:(4):1985;232-235.
89. Moraes-Pinto M.I., Verhoeff F., Chimsuku L., Milligan P.J., Wesumperuma L., Broadhead R.L., Brabin B.J., Johnson P.M., Hart C.A. Placental antibody transfer: influence of maternal HIV infection and placental malaria. Arch. Dis. Child. Fetal. Neonatal. Ed. 79:(3):1998;F202-F205.
90. Moss W.J., Cutts F.T., Griffin D.E. Implications of the human immunodeficiency virus epidemic for control and eradication of measles. Clin. Infect. Dis. 29:(1):1999;106-112.
91. Moss W.J., Polack F.P. Immune responses to measles and measles vaccine: challenges for measles control. Viral. Immunol. 14:(4):2001;297-309.
92. Mossong J., Nokes D.J., Edmunds W.J., Cox M.J., Ratnam S., Muller C.P. Modeling the impact of subclinical measles transmission in vaccinated populations with waning immunity. Am. J. Epidemiol. 150:(11):1999;1238-1249.
93. Msamanga, G.I. 1986. Impact of Measles Immunization on Nutritional Status and Mortality in Tanzania, PhD, Harvard School of Public Health, Boston.
94. Narain J.P., Khare S., Rana S.R., Banerjee K.B. Epidemic measles in an isolated unvaccinated population, India. Int. J. Epidemiol. 18:(4):1989;952-958.
95. National Institute of Allergy and Infectious Diseases, B. 2000. Accelerated Development of Vaccines.
96. Nokes D.J., Anderson R.M. Measles, mumps, and rubella vaccine: what coverage to block transmission? [letter]. Lancet. 2:(8624):1988;1374.
97. Nokes D.J., McLean A.R., Anderson R.M., Grabowsky M. Measles immunization strategies for countries with high transmission rates: interim guidelines predicted using a mathematical model. Int. J. Epidemiol. 19:1990;703-710.
98. Nyarko, P., Pence, B., Debpuur, C. 2001. Immunization status and child survival in rural Ghana., Population Council, New York, Working papers no. 147.
99. Okoko J.B., Wesuperuma L.H., Ota M.O., Banya W.A., Pinder M., Gomez F.S., Osinusi K., Hart A.C. Influence of placental malaria infection and maternal hypergammaglobulinaemia on materno-foetal transfer of measles and tetanus antibodies in a rural west African population. J. Health Popul. Nutr. 19:(2):2001;59-65.
100. Okoko J.B., Wesumperuma H.L., Hart C.A. The influence of prematurity and low birthweight on transplacental antibody transfer in a rural West African population. Trop. Med. Int. Health. 6:(7):2001;529-534.
101. Orenstein W.A., Bernier R.H., Dondero T.J., Hinman A.R., Marks J.S., Bart K.J., Sirotkin B. Field evaluation of vaccine efficacy. Bull. Who. 63:1985;1055-1068.
102. Orenstein W.A., Bernier R.H., Hinman A.R. Assessing vaccine efficacy in the field. Further observations. Epidemiol. Rev. 10:1988;212-241.
103. Pabst H.F., Spady D.W., Carson M.M., Krezolek M.P., Barreto L., Wittes R.C. Cell-mediated and antibody immune responses to AIK-C and connaught monovalent measles vaccine given to 6 month old infants. Vaccine. 17:(15-16):1999;1910-1918.
104. Paunio M., Peltola H., Valle M., Davidkin I., Virtanen M., Heinonen O.P. Explosive school-based measles outbreak: intense exposure may have resulted in high risk, even among revaccinees. Am. J. Epidemiol. 148:(11):1998;1103-1110.
105. Paunio M., Peltola H., Valle M., Davidkin I., Virtanen M., Heinonen O.P. Twice vaccinated recipients are better protected against epidemic measles than are single dose recipients of measles containing vaccine. J. Epidemiol. Community Health. 53:(3):1999;173-178.
106. Pedersen I.R., Mordhorst C.H., Glikmann G., von Magnus H. Subclinical measles infection in vaccinated seropositive individuals in arctic Greenland. Vaccine. 7:(4):1989;345-348.
107. Peltola H., Heinonen O.P., Valle M., Paunio M., Virtanen M., Karanko V., Cantell K. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program. New Engl. J. Med. 331:(21):1994;1397-1402.
108. Phadke M.A., Bhargava I., Dhaigude P., Bagade A., Biniwale M.A., Kurlekar S.U. Efficacy of two dose measles vaccination in a community setting. Indian Pediatr. 35:(8):1998;723-725.
109. Polack F.P., Lee S.H., Permar S., Manyara E., Nousari H.G., Jeng Y., Mustafa F., Valsamakis A., Adams R.J., Robinson H.L., Griffin D.E. Successful DNA immunization against measles: neutralizing antibody against either the hemagglutinin or fusion glycoprotein protects rhesus macaques without evidence of atypical measles. Nat. Med. 6:(7):2000;776-781.
110. Poland G.A., Jacobson R.M., Schaid D., Moore S.B., Jacobsen S.J. The association between HLA class I alleles and measles vaccine-induced antibody response: evidence of a significant association. Vaccine. 16:(19):1998;1869-1871.
111. Rau A.T., Dhulia A., Wilson C.G., Chopra G.S., Sarkar P.K. Transaplacentally transmitted anti-measles antibodies in term and preterm infants. Indian Pediatr. 39:(3):2002;282-288.
112. Redd S.C., Markowitz L.E., Katz S.L. Measles vaccine. Plotkin S.A., Orenstein W.A. Vaccines. Third ed. 1999;222-266 W.B Saunders Company.
113. Richard-Lenoble D., Kombila M., Guillemot F., Monjour L., Gendrel D. Vaccination antirougeoleuse e paludisme. Arch. Fr. Pediare. 44:1987;817-819.
114. Rosenthal S.R., Clements C.J. Two-dose measles vaccination schedules. Bull. Who. 71:(3/4):1993;421-428.
115. Samb B., Aaby P., Whittle H.C., Seck A.M., Rahman S., Bennett J., Markowitz L.E., Simondon F. Serologic status and measles attack rates among vaccinated and unvaccinated children in rural Senegal. Pediatr. Infect. Dis. J. 14:1995;203-209.
116. Samb B., Whittle H.C., Aaby P., Seck A.M.C., Bennett J., Markowitz L.E., Ngom P.T., Zeller H., Michaelsen K.F., Simondon F. No evidence of long-term immunosuppression after high-titer Edmonston-Zagreb measles vaccination in Senegal. J. Infect. Dis. 171:1995;506-508.
117. Samb, B., Aaby, P., Whittle, H.C., Seck, A.M.C., Simondon, F. 1997. Decline in Measles Case Fatality Ratio after the Introduction of Measles Immunization in Rural Senegal. Am. J. Epidemiol., 145 (1).
118. Schlereth B., Germann P.G., ter M.V., Niewiesk S. DNA vaccination with both the haemagglutinin and fusion proteins but not the nucleocapsid protein protects against experimental measles virus infection. J. Gen. Virol. 81 Pt 5:2000;1321-1325.
119. Schlereth B., Rose J.K., Buonocore L., ter M.V., Niewiesk S. Successful vaccine-induced seroconversion by single-dose immunization in the presence of measles virus-specific maternal antibodies. J. Virol. 74:(10):2000;4652-4657.
120. Scott S., Cutts F.T., Nyandu B. Mild illness at or after measles vaccination does not reduce seroresponse in young children. Vaccine. 17:(7-8):1999;837-843.
121. Semba R.D., Munasir Z., Beeler J., Akib A., Muhilal, Audet S., Sommer A. Reduced seroconversion to measles in infants given vitamin A with measles vaccination. Lancet. 345:1995;1330-1332.
122. Semba R.D., Akib A., Beeler J., Munasir Z., Permaesih D., Muherdiyantiningsih K.omala, Martuti S., Muhilal. Effect of vitamin A supplementation on measles vaccination in nine- month-old infants. Public Health. 111:(4):1997;245-247.
123. Shann F. A little bit of measles does you good. Even if measles is eradicated, immunisation may still be desirable in developing countries [editorial]. Br. Med. J. 319:(7201):1999;4-5.
124. Sheldon T. Netherlands faces measles epidemic [news]. Br. Med. J. 320:(7227):2000;76.
125. Siegrist C.-A., Barrios C., Martinez X., Brandt C., Berney M., Cordova M., Kovarik J., Lambert P.H. Influence of maternal antibodies on vaccine responses: inhibition of antibody but not T cell responses allows successful early prime-boost strategies in mice. Eur. J. Immunol. 28:(12):1998;4138-4148.
126. Singh J., Kumar A., Rai R.N., Khare S., Jain D.C., Bhatia R., Datta K.K. Widespread outbreaks of measles in rural uttar pradesh, India, 1996: high risk areas and groups [In Process Citation]. Indian Pediatr. 36:(3):1999;249-256.
127. Smedman L., da Silva M.C., Gunnlaugsson G., Norrby E., Zetterstrom R. Augmented antibody response to live attenuated measles vaccine in children with Plasmodium falciparum parasitaemia. Ann. Trop. Paediatr. 6:1986;149-153.
128. Sniadack D.H., Moscoso B., Aguilar R., Heath J., Bellini W.J., Chiu M.C. Measles epidemiology and outbreak response immunization in a rural community in Peru. Bull. Who. 77:(7):1999;545-552.
129. St Sauver J.L., Ovsyannikova I.G., Jacobson R.M., Jacobsen S.J., Vierkant R.A., Schaid D.J., Pankratz V.S., Green E.M., Poland G.A. Associations between human leukocyte antigen homozygosity and antibody levels to measles vaccine. J. Infect. Dis. 185:(11):2002;1545-1549.
130. Stittelaar K.J., Wyatt L.S., de Swart R.L., Vos H.W., Groen J., van Amerongen G., van Binnendijk R.S., Rozenblatt S., Moss B., Osterhaus A.D. Protective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles virus vaccine in the presence of passively acquired antibodies. J. Virol. 74:(9):2000;4236-4243.
131. Strebel P., Guris D., Papania M., Cochi S. Invited commentary: vaccine failure or failure to vaccinate? Am. J. Epidemiol. 149:(4):1999;302-303.
132. Taylor W.R., KaLisa R., Ma-Disu M., Weinman J.M. Measles control in urban Africa complicated by high incidence of measles in the first year of life. Am.J. Epidemiol. 127:1988;788-794.
133. The Kasongo Project Team 1981. Influence of measles vaccination on survival pattern of 7-35-month-old children in Kasongo, Zaire. Lancet pp. 764-767.
134. Tidjani O., Grunitsky B., Guerin N., Levy-Bruhl D., Lecam N., Xuereff C., Tatagan K. Serological effects of Edmonston-Zagreb, Schwarz, and AIK-C measles vaccine strains given at ages 4-5 or 8-10 months [see comments]. Lancet. 2:(8676):1989;1357-1360.
135. Tsai H.Y., Huang L.M., Shih Y.T., Chen J.M., Jiang T.M., Tsai C.H., Lee C.Y. Immunogenicity and safety of standard-titer AIK-C measles vaccine in nine-month-old infants. Viral. Immunol. 12:(4):1999;343-348.
136. van Binnendijk R.S., Poelen M.C.M., van Amerongen G., de Vries P., Osterhaus A.D. Protective immunity in macaques vaccinated with live attenuated, recombinant, and subunit measles vaccines in the presence of passively acquired antibodies. J. Infect. Dis. 175:(3):1997;524-532.
137. Vardas E., Kreis S. Isolation of measles virus from a naturally-immune, asymptomatically re- infected individual. J. Clin. Virol. 13:(3):1999;173-179.
138. Velema J.P., Alihonou E.M., Gandaho T., Hounye F.H. Childhood mortality among users and non-users of primary health care in a rural West African community. Int. J. Epidemiol. 20:(2):1991;474-479.
139. Vitek C.R., Aduddell M., Brinton M.J., Hoffman R.E., Redd S.C. Increased protections during a measles outbreak of children previously vaccinated with a second dose of measles-mumps-rubella vaccine. Pediatr. Infect. Dis. J. 18:(7):1999;620-623.
140. Wairagkar N.S., Shaikh N.J., Udavant P., Banerjee K. Isolation of measles virus below 4 months of age during an outbreak in Pune, India. Lancet. 351:1998;495-496.
141. Wesumperuma H.L., Perera A.J., Pharoah P.O., Hart C.A. The influence of prematurity and low birthweight on transplacental antibody transfer in Sri Lanka. Ann. Trop. Med. Parasitol. 93:(2):1999;169-177.
142. Whittle, H.C., Rowland, M.G.M., Mann, G.F., Lamb, W.H., Lewis, R.A. 1984, Immunisation of 4-6 month old Gambian infants with Edmonston-Zagreb measles vaccine, Lancet no. October 13, pp. 834-837.
143. Whittle H.C., Hanlon P., O'Neill K., Hanlon L., Marsh V., Jupp E., Aaby P. Trial of high-dose Edmonston-Zagreb measles vaccine in the Gambia: antibody response and side-effects. Lancet. 2:1988;811-814.
144. Whittle H.C., Mann G., Eccles M. Effects of dose and strain of vaccine on success of measles vaccination of infants aged 4-5 months. Lancet. i:1988;963-966.
145. Whittle H.C., Aaby P., Samb B., Cisse B., Kanteh F., Soumaré M., Bennett J., Simondon F. Poor serological responses 5-7 years after immunization with high and standard titre measles vaccines. Pediatr. Infect. Dis. J. 18:(1):1999;53-57.
146. Whittle H.C., Aaby P., Samb B., Jensen H., Bennett J., Simondon F. Effect of subclinical infection on maintaining immunity against measles in vaccinated children in West Africa. Lancet. 353:(9147):1999;98-102.
147. Measles. Progress towards global control and regional elimination, 1998-1999. Wkly. Epidemiol. Rec. 74:(50):1999;429-434.
148. Strategies for reducing global measles mortality. Wkly. Epidemiol. Rec. 75:(50):2000;411-416.
149. Global measles mortality reduction and regional elimination, 2000-2001. Part I. Wkly. Epidemiol. Rec. 77:(7):2002;50-55.